London-listed Hikma Pharmaceuticals (LSE: HIK) today reports its preliminary audited results for the year ended December 31, 2020, that disappointed and saw the firm’s share fall 7.9% to 2,227 pence in early trading.
Hikma reported core operating profit of $566 million, which missed a consensus forecast for $574 million. Group sales for the year were $2,341 million, just a fraction above consensus forecasts fo $2,340 million.
Core Group revenue growth of 6%, reflected growth in all three businesses, said Hikma. Core operating profit was up 11%, driven by strong growth in profit of Generics, with sales of $744 million, and Injectables, at $977 million, Branded sales were $613 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze